NEW YORK, November 1, 2016 /PRNewswire/ --
On Monday, October 31, 2016, the NASDAQComposite ended the trading session at 5,189.13, down 0.02%; the Dow Jones Industrial Average edged 0.10% lower, to finish at 18,142.42; and the S&P 500 closed at 2,126.15, down 0.01%. Despite major US indices bearish performance, US markets saw
Morristown, New Jersey headquartered Pernix Therapeutics Holdings Inc.'s stock finished Monday's session 4.05% lower at $3.55 with a total volume of 297,828 shares traded. Over the last one month and over the previous three months, Pernix Therapeutics' shares have rallied 470.65% and 309.60%, respectively. Furthermore, the stock has gained 26.33% in the past one year. Shares of the Company, which develops, manufactures, markets, and sells pharmaceutical products, are trading above its 50-day and 200-day moving averages by 168.79% and 213.92%, respectively. Pernix Therapeutics' stock has a Relative Strength Index (RSI) of 66.86. Sign up and read the free research report on PTX at:
On Monday, shares in Bagsvaerd, Denmark headquartered Novo Nordisk A/S recorded a trading volume of 9.06 million shares, which was higher than their three months average volume of 3.58 million shares. The stock ended the day 0.34% lower at $35.54. Shares of the Company, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, are trading at a PE ratio of 17.18. Novo Nordisk's stock is trading below its 50-day and 200-day moving averages by 18.39% and 29.91%, respectively. Furthermore, shares of Novo Nordisk have an RSI of 22.87.
Yesterday, research firm DNB Markets downgraded the Company's stock rating from 'Buy' to 'Hold'. The complimentary research report on NVO can be downloaded at:
New York headquartered Synergy Pharmaceuticals Inc.'s stock declined 3.57%, to close the day at $4.59. The stock recorded a trading volume of 2.14 million shares. Shares of Synergy Pharma, which focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases, have advanced 11.68% in the past three months. The Company's shares are trading 14.50% above its 200-day moving average. Additionally, the stock has an RSI of 30.95. Register for free on Stock-Callers.com and access the latest report on SGYP at:
On Monday, shares in San Diego, California headquartered Apricus Biosciences Inc. ended the session 10.67% lower at $2.01 with a total volume of 65,846 shares traded. Apricus Biosciences' stock is trading 40.75% below its 50-day moving average and 65.28% below its 200-day moving average. Moreover, shares of the Company, which focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology, have an RSI of 24.33. Get free access to your research report on APRI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All